Skip to main content

Table 6 Summary of other FDA-approved anticancer therapies investigated in current study by category and subcategory

From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States

Drug category Drug name Indicated for breast cancer Labeled indications if not indicated for breast cancer (ICD-9-CM codes) Initial FDA approval during study period
Hormone therapies Anastrozole Yes   1995
  Exemestane Yes   1999
  Fluoxymesterone Yes   1956
  Fulvestrant Yes   April 2002
  Goserelin Yes   1989
  Letrozole Yes   1997
  Leuprolide No 185 1985
  Tamoxifen Yes   1977
Targeted therapies Bortezomib No   May 2003
  Erlotinib No   November 2004
  Imatinib No 150-154, 158.0, 159.0, 159.8, 159.9, 171.5-171.9, 205.1, 205.9, 238.1, 239 May 2001
  Sorafenib No 155.0, 155.2, 197.7, 189.0, 189.8, 189.9, 198.0 December 2005
Immunotherapies Aldesleukin No 172, 189.0, 189.1, 189.8, 189.9, 198.0, 198.2 1992
  Alemtuzumab No 204.1, 204.9 May 2001
  Bevacizumab Yes1 153, 154, 162.2-162.5, 162.8, 162.9, 191, 197.0, 197.5, 198.3 February 20042
  Cetuximab No 140-149, 153, 154, 160, 161, 173.0-173.4, 195.0, 197.5 February 2004
  Denileukin diftitox No 202.1, 202.2 1999
  Gemtuzumab ozogamicin No 205.0, 205.9 2000
  Panitumumab No 153, 154, 197.5 September 2006
  Rituximab3 No 200, 202, 204.1, 204.9, 714 1997
  Thalidomide No 0.17.1, 695.2, 203.0 1998
  Trastuzumab Yes   1998
  1. 1Breast cancer indication approved by FDA on February 22, 2008 and revoked in November 2011.
  2. 2Colorectal cancer indication approved in February 2004, Non-small cell lung carcinoma in October 2006, Glioblastoma in May 2009.
  3. 3Obtained FDA approval for Wegener’s Granulomatosis (WG) and Microscopic Polyngiitis (MPA) only in April 2011 (post-study period).